av片亚洲国产男人的天堂,久久久久人妻一区精品色奶水 ,综合网久久

肽T

NMR下載 COA and HPLC MSDS下載
names：
Peptide T
CAS號：
106362-32-7
MDL Number：
MF(分子式)： C35H55N9O16 MW(分子量)： 857.86
EINECS: Reaxys Number:
Pubchem ID:73352 Brand:BIOFOUNT

Peptide T(肽T,106362-32-7)又稱為N-（N-（N（2）-（N-（N-（N-（ND-丙氨?；鵏-絲氨酰基）-L-蘇氨?；?L-蘇氨?；㎜-蘇氨?；?L-天冬酰胺基）-L-酪氨酸）L-蘇氨酸。Peptide T與HIV包膜蛋白gp120共享序列同源性?？赡艿淖饔脵C制是 gp120 對 CD4 受體的競爭性抑制以及與血管腸肽受體的結合和抑制細胞因子作用.Peptide T 可能在艾滋病治療中用作抗病毒藥。五肽核心序列TTNYT由肽T中的氨基酸4-8組成，是附著至CD4受體所需的HIV包膜序列。

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
YZM000698-5mg	5mg	>97%hc	￥ 2936.00	￥ 2936.00		Backorder	- +	￥ 0.00
YZM000698-1mg	1mg	>97%hc	￥ 675.00	￥ 675.00		1-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	肽T(106362-32-7);HIV肽T;肽T;肽T，HIV;H-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-OH; L-丙氨酰-L-絲氨酰-L-蘇氨酸-L-蘇氨酸-L-蘇氨酸-L-天冬酰胺-L-酪氨酰-L-蘇氨酸; （2S，3R）-2-[[（2S）-2-[[（2S）-4-氨基-2-[[（2S，3R）-2-[[（2S，3R）-2-[[ （2S，3R）-2-[[（（2S）-2-[[（2S）-2-氨基丙?；鵠氨基] -3-羥基丙?；鵠氨基] -3-羥基丁?；鵠氨基] -3-羥基丁?；鵠氨基]- 3-羥基丁酰基]氨基] -4-氧丁?；鵠氨基] -3-（4-羥基苯基）丙酰基]氨基] -3-羥基丁酸；HIV肽T; 肽T; 肽T，HIV;
英文別名	Peptide T(106362-32-7);HIV Peptide T;Peptide T;Peptide T, HIV; H-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-OH; L-alanyl-L-seryl-L-threonyl-L-threonyl-L-threonyl-L-asparagyl-L-tyrosyl-L-threonine; (2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoic acid; HIV Peptide T; Peptide T; Peptide T, HIV;
CAS號	106362-32-7
Inchi	1S/C35H55N9O16/c1-13(36)28(52)40-22(12-45)31(55)41-25(15(3)47)33(57)43-26(16(4)48)34(58)42-24(14(2)46)32(56)39-21(11-23(37)51)29(53)38-20(10-18-6-8-19(50)9-7-18)30(54)44-27(17(5)49)35(59)60/h6-9,13-17,20-22,24-27,45-50H,10-12,36H2,1-5H3,(H2,37,51)(H,38,53)(H,39,56)(H,40,52)(H,41,55)(H,42,58)(H,43,57)(H,44,54)(H,59,60)/t13-,14+,15+,16+,17+,20-,21-,22-,24-,25-,26-,27-/m0/s1
InchiKey	IWHCAJPPWOMXNW-LYKMMFCUSA-N
分子式 Formula	C35H55N9O16
分子量 Molecular Weight	857.86
溶解度Solubility
性狀	Solid
儲藏條件 Storage conditions	存放在陰涼干燥處

肽T(Peptide T,106362-32-7)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時實驗操作需要手套箱內(nèi)完成以免對實驗人員造成傷害
3.實驗后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags：肽T試劑,肽T雜質(zhì),肽T中間體,肽T密度,肽T旋光度,肽T溶解度,肽T閃點,肽T結構式,肽T購買,肽T熔點,

產(chǎn)品說明	肽T(Peptide T,106362-32-7)是源自HIV-1 gp120的V2區(qū)的八肽
Introduction	肽T(Peptide T,106362-32-7) is an octapeptide from the V2 region of HIV gp120. Peptide T is a ligand for theCD4receptor and prevents binding of HIVto the CD4 receptor.
Application1	Peptide T是源自HIV-1 gp120的V2區(qū)的八肽。 Peptide T是 CD4 受體的配體，可阻止 HIV 與CD4受體結合。
Application2
Application3

肽T(Peptide T,106362-32-7)藥理學：

肽T是一種HIV進入抑制劑，它通過阻斷趨化因子5受體（CCR5）發(fā)揮作用，目前正在臨床試驗中，用于治療HIV相關的神經(jīng)和體質(zhì)癥狀。

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

1.Ruff MR, et al. Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attachment. Lancet. 1987 Sep 26;2(8561):751.

2.Ruff MR, et al. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. 2001 Oct;52(1):63-75.

3.Raychaudhuri SP, et al. Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines. Int J Immunopharmacol. 1999 Sep;21(9):609-15.

4.Sáez-Torres I, et al. Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol. 2000 Jul;121(1):151-6.

5Syntheses of mucin-type O-glycopeptides and oligosaccharides using transglycosylation and reverse-hydrolysis activities of Bifidobacterium endo-α-N-acetylgalactosaminidase Glycoconjugate Journal 2009

肽T(Peptide T,106362-32-7)參考文獻：

1.Phosphoenolpyruvate-dependent phosphotransferase system of Staphylococcus aureus: factor IIIlac, a trimeric phospho-carrier protein that also acts as a phase transfer catalyst.
Deutscher J;Beyreuther K;Sobek HM;Stüber K;Hengstenberg W Biochemistry. 1982 Sep 28;21(20):4867-73.

Factor IIIlac (FIII) consists of three identical subunits. It could be shown that each of the subunits carries a phosphoryl group upon phosphorylation (P-FIII) with phosphoenolpyruvate (PEP), enzyme I, and histidine-containing phospho-carrier protein (HPr). The phosphoryl group is bound to a histidyl residue in P-FIII. Each subunit of FIII contains four histidyl residues. After tryptic cleavage a peptide was isolated that contained one other histidyl residue besides the active center histidine. By further cleavage of the peptide T-2 with V-8 Staphylococcus aureus protease it could be shown that His-19 in the sequence of the peptide T-2 is the active center histidine. Another peptide (1-38), caused by incomplete tryptic cleavage, could be isolated. It inhibited the phospho-transfer reaction from PEP to the sugar molecule at the step of factor III-enzyme II recognition. It competes with factor III for the binding site of enzyme II, the membrane component. It is a very hydrophobic peptide. This hydrophobic region is buried in factor III. But upon phosphorylation of factor III it is turned out. Thus P-FIII binds to Triton X-100 micelles whereas factor III does not. This conformational change caused by phosphorylation could be shown by proton nuclear magnetic resonance methods [Kalbitzer, H.

2.Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.
Heseltine PN;Goodkin K;Atkinson JH;Vitiello B;Rochon J;Heaton RK;Eaton EM;Wilkie FL;Sobel E;Brown SJ;Feaster D;Schneider L;Goldschmidts WL;Stover ES Arch Neurol. 1998 Jan;55(1):41-51.

BACKGROUND: ;Cognitive impairment is a common consequence of human immunodeficiency virus (HIV) infection, and dementia is one of the diseases that defines the acquired immunodeficiency syndrome. Peptide T (d-ala-peptide-T-amide) has been reported to block the binding of gp120 to brain tissue and to protect neurons from the toxic effects of gp120 in vitro. In pilot studies, administration of peptide T to HIV-positive patients with cognitive impairment was associated with improvement in cognition and constitutional symptoms.;OBJECTIVE: ;To determine whether the intranasal administration of peptide T would improve cognitive function of HIV-positive patients with cognitive impairment.;PATIENTS AND METHODS: ;This was a 3-site, double-blind, placebo-controlled trial of peptide T given intranasally at a dosage of 2 mg 3 times a day for 6 months. Participants were HIV-seropositive persons with evidence of cognitive deficits on a screening test battery. Concomitant antiretroviral therapy was allowed. Randomization to the 2 study arms was balanced according to several stratification variables, such as CD4+ cell count, severity of cognitive impairment, and antiretroviral therapy at study entry.

3.A 500 MHz study of peptide T in a DMSO solution.
Picone D;Temussi PA;Marastoni M;Tomatis R;Motta A FEBS Lett. 1988 Apr 11;231(1):159-63.

Peptide T, an octapeptide of sequence ASTTTNYT that binds to human T cells, was studied as a zwitterion in DMSOd6 solution by means of proton NMR spectroscopy at 500 MHz. The unusual dispersion of the resonances of residues of the same type (T) makes it possible to assign all resonances to specific residues by means of several 2D techniques. The non-random nature of the conformation is substantiated by the observation of sequential nuclear Overhauser enhancements (NOEs). The low value of the temperature coefficient of the chemical shift of the NH of T8 and a diagnostic NOE between the NHs of T7 and T8 hint that a beta-turn including T5, N6, Y7 and T8 is a prominent conformational feature in solution. The ring current high field shifts of the methyl group and of the NH of T8 are consistent with an interaction with the side-chain of Y7, favoured by the beta-turn.

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開